1. Introduction {#sec1-cancers-11-01360}
===============

Current guidelines recommend routine molecular testing for patients with metastatic non-small cell lung cancer (NSCLC) \[[@B1-cancers-11-01360],[@B2-cancers-11-01360]\]. In those identified to have tumors with actionable somatic alterations, target-specific tyrosine kinase inhibitors (TKIs) are the preferred first-line treatment \[[@B1-cancers-11-01360]\]. The most common such genetic alteration is a mutation in the epidermal growth factor receptor (*EGFR*) gene \[[@B3-cancers-11-01360],[@B4-cancers-11-01360]\]. Five drugs targeting *EGFR*-mutant NSCLC are currently FDA-approved as front-line therapy \[[@B5-cancers-11-01360],[@B6-cancers-11-01360],[@B7-cancers-11-01360],[@B8-cancers-11-01360],[@B9-cancers-11-01360]\].

This trend towards personalized, precision medicine in the treatment of NSCLC and the indispensable nature of imaging in the management of NSCLC have led to increased interest in radiogenomics and the correlation of radiologic features with genetic mutations. Several groups have investigated and reported the imaging findings of different genetic mutational subtypes in NSCLC \[[@B10-cancers-11-01360],[@B11-cancers-11-01360],[@B12-cancers-11-01360],[@B13-cancers-11-01360],[@B14-cancers-11-01360],[@B15-cancers-11-01360]\]. Imaging features that have been associated with the primary tumor in *EGFR*-mutant NSCLC include peripheral location, pleural tagging, air bronchograms, and ground-glass opacities \[[@B16-cancers-11-01360],[@B17-cancers-11-01360],[@B18-cancers-11-01360]\]. Several authors have also reported the increased frequency of diffuse lung metastases, also referred to as "miliary metastases" by some authors, in the setting of *EGFR* mutation-positive NSCLC \[[@B19-cancers-11-01360],[@B20-cancers-11-01360],[@B21-cancers-11-01360]\].

To our knowledge, no study has investigated imaging features and patterns of metastases that may be associated with *EGFR*-mutant NSCLC with diffuse lung metastases. The goals of our study were to assess the incidence of diffuse lung metastases in *EGFR*-mutant and *EGFR* wild-type NSCLC on imaging and to assess other imaging features that may be associated with diffuse lung metastases in *EGFR*-mutant NSCLC.

2. Results {#sec2-cancers-11-01360}
==========

2.1. Patients {#sec2dot1-cancers-11-01360}
-------------

The 217 patients studied included 117 patients with *EGFR*-mutant NSCLC and 100 patients with *EGFR* wild-type NSCLC and no documented driver mutation ([Table 1](#cancers-11-01360-t001){ref-type="table"}). The median age was 65 years (range 26--90) and the majority was female (57%) and were current or previous smokers (59%). As expected, those with *EGFR*-mutant NSCLC were more likely to be female, never-smokers.

The frequency of diffuse lung metastases was significantly higher in *EGFR*-mutant patients (18% vs. 3%, *p* \< 0.01). *EGFR*-positive patients were also more likely to have nodal disease (*p* \< 0.01), pleural metastases (*p* \< 0.01), and adrenal metastases (*p* \< 0.01).

2.2. Diffuse Lung Metastases in EGFR-Mutant NSCLC {#sec2dot2-cancers-11-01360}
-------------------------------------------------

Among *EGFR*-mutant patients, we examined the characteristics of those with and without diffuse metastases ([Table 2](#cancers-11-01360-t002){ref-type="table"}). The presence of a metastatic nodule \>6 mm was inversely correlated with the presence of diffuse lung metastases (*p* \< 0.01).

2.3. Multivariable Regression Model for Presence of Diffuse Lung Metastases in The Setting of EGFR-Mutation {#sec2dot3-cancers-11-01360}
-----------------------------------------------------------------------------------------------------------

Age (≥63, \<63), zone, and lung metastases \>6mm are significant predictors of whether patients had diffuse lung disease metastases or not. When holding the other covariates fixed, among *EGFR*-mutant patients, the odds of having diffuse lung metastases are 87% lower in those with lung metastases \>6 mm than those without lung metastasis \>6 mm (OR: 0.13, 95% CI: 0.04--0.41).

3. Discussion {#sec3-cancers-11-01360}
=============

Our findings add to the growing evidence that there is increased frequency of diffuse lung metastases in the setting of *EGFR*-mutant NSCLC. We also found that the presence of diffuse lung metastases in the setting of *EGFR*-mutant NSCLC is inversely correlated with the presence of larger discrete metastatic nodules.

In our cohort, there was almost a six-fold increased incidence (18% vs. 3%) of diffuse lung metastases in patients with metastatic *EGFR*-mutant NSCLC compared to patients with *EGFR*-wild type NSCLC. Other studies have reported rates of 12--50% \[[@B17-cancers-11-01360],[@B21-cancers-11-01360],[@B22-cancers-11-01360]\]. Differences in frequencies among several studies may be, at least in part, due to the differences in defining the finding of diffuse lung metastases and miliary metastases. We adhered to a stricter definition (i.e., diffuse nodules ≤6 mm in size), while others have used the size cut-off of up to 30 mm \[[@B22-cancers-11-01360]\].

Prior clinical- and population-based studies have also reported the increased frequency of "miliary metastases" in the setting of *EGFR*-mutant NSCLC \[[@B19-cancers-11-01360],[@B20-cancers-11-01360],[@B21-cancers-11-01360]\]. Another retrospective study also reported higher incidence of *EGFR* mutations in those who present with miliary metastases compared to those who do not have miliary metastases \[[@B23-cancers-11-01360]\]. While several authors have used the term "miliary" metastasis in the setting of *EGFR*-mutant NSCLC, we propose that the designation of "diffuse lung metastases" is more accurate.

Miliary nodular pattern of disease has distinct radiologic features characterized by diffuse, bilateral infiltration of the lungs by tiny, typically 1--4 mm in size, nodules likened to millet seeds \[[@B24-cancers-11-01360]\]. This finding is seen in numerous infectious and inflammatory etiologies, including tuberculosis, histoplasmosis, silicosis, and sarcoidosis \[[@B25-cancers-11-01360],[@B26-cancers-11-01360],[@B27-cancers-11-01360],[@B28-cancers-11-01360],[@B29-cancers-11-01360],[@B30-cancers-11-01360]\]. Miliary nodular patterns have also been in the setting of metastatic disease, most notably with primary thyroid cancer, renal cell carcinoma, and melanoma \[[@B24-cancers-11-01360],[@B25-cancers-11-01360]\]. While the imaging features of diffuse lung metastases in *EGFR*-mutant NSCLC may overlap with the other pathologies that present with miliary nodules, *EGFR*-mutant NSCLC with diffuse lung metastases can by distinguished by the presence of a dominant primary lung mass or nodule ([Figure 1](#cancers-11-01360-f001){ref-type="fig"}).

Of note, our findings also suggest that the presence of a larger (\>6 mm) discrete lung metastasis is inversely correlated with diffuse lung metastases in the setting of *EGFR*-mutant NSCLC. It is unclear as to why those with diffuse lung metastases are less likely to have concomitant larger metastatic nodules, but it suggests a distinct mechanism of spread. We hypothesize that this may be due to the diffuse synchronous development of the nodules, which may lead to worse symptomatology and presentation before nodules have time to increase in size.

We did not find any other significant associations between the presence of diffuse lung metastases and tumor morphology, size, and location of primary tumor and the presence of lymphangitic carcinomatosis, pleural metastasis, and other distant metastases in the setting of *EGFR* mutations. Although some investigators have suggested that the exon-19 deletion subtype of *EGFR* may be associated with increased tendency for miliary metastases \[[@B23-cancers-11-01360],[@B31-cancers-11-01360]\], our findings did not support this. A larger study cohort may be needed to validate these reports.

The single-institution, retrospective nature of our study predisposes it to selection bias and limits the findings' generalizability to larger populations. Our relatively small cohort may also limit the study's statistical power in discovering associations or lack thereof between diffuse lung metastases and other imaging features of *EGFR*-mutant NSCLC patients. Again, a larger cohort, perhaps from a collaborative multicenter study, would be helpful in validating our findings and in resolving these limitations.

Although the presence of diffuse lung metastases in the setting of NSCLC may be suggestive of an underlying *EGFR* mutation, this feature does not replace molecular genotyping. Testing for *EGFR* mutations in NSCLC traditionally depended on unmodified Sanger sequencing, which requires at least 50% malignant cellularity to be reliable \[[@B2-cancers-11-01360],[@B32-cancers-11-01360]\]. Subsequently, however, more sensitive PCR-based targeted methods have been developed and validated, requiring as little as 10% tumor content \[[@B2-cancers-11-01360],[@B33-cancers-11-01360],[@B34-cancers-11-01360],[@B35-cancers-11-01360]\]. Although more sensitive, these methods still require adequate tissue for accurate diagnosis. Tissue sampling and subsequent testing can take time and potentially delay initiation of treatment. Another factor that can prolong time to diagnosis and treatment is the timing of testing. In many centers, including ours, it is still customary for the treating physician to decide if a tumor specimen should be tested for genetic mutations, as opposed to reflex testing, wherein a pathologist decides which specimens should be tested for genetic mutations, which can further delay diagnosis and treatment \[[@B36-cancers-11-01360],[@B37-cancers-11-01360]\].

The presence of diffuse lung metastasis in the setting of NSCLC should increase the suspicion for the presence of *EGFR* mutation. This may be assistive in determining which patients may potentially benefit from expedited molecular testing and those who may benefit from repeat alternative testing following an unexpectedly negative or discordant result initial testing.

4. Materials and Methods {#sec4-cancers-11-01360}
========================

4.1. Patient Selection {#sec4dot1-cancers-11-01360}
----------------------

Under an institutional "Partners Human Research" (the Massachusetts General Hospital IRB) review board-approved protocol (protocol number: 2019P000198), we searched our clinical database for patients with biopsy-proven stage IV NSCLC who had undergone genetic testing and found to have activating *EGFR* mutations between January 2010 and December 2013 and who also had CT and or PET/CT scans performed prior to any anti-cancer therapy either at our hospital or at an outside facility with the images uploaded in to our picture archiving and communication system. For controls, we selected a subset of NSCLC patients with genetic testing who were wild-type for *EGFR*, negative for other potentially targetable mutations (e.g., *ALK*, *ROS1*, *RET*, etc), and had similar pre-treatment imaging available for review.

4.2. Genetic Analysis {#sec4dot2-cancers-11-01360}
---------------------

Genotyping was performed using a multiplex PCR-based assay (SNaPshot^®^ platform, Applied Biosystems, Foster City, CA, USA). This system detects single nucleotide polymorphisms in 14 key cancer genes and more than 50 hotspot mutations \[[@B2-cancers-11-01360],[@B38-cancers-11-01360]\]. The genetic testing was performed on formalin-fixed paraffin-embedded biopsy specimens that were obtained from different organs via surgical, bronchoscopic, or image guided percutaneous procedures.

4.3. CT Imaging Protocol {#sec4dot3-cancers-11-01360}
------------------------

The CT examinations of the body (chest, abdomen, and pelvis) were performed on multidetector-row CT scanners with helical acquisition mode, automatic exposure control, tube potential 100--120 kV, slice thickness of 1--2.5 mm for chest and 5 mm for abdomen. The brain MR and/or CT images were reviewed for the presence of metastases. The 18-FDG PET images, when available, were reviewed to assess for metabolic activity and were correlated with CT images.

4.4. Image Analysis {#sec4dot4-cancers-11-01360}
-------------------

The cross-sectional imaging studies were independently reviewed by a board-certified thoracic radiologist (SRD) and a thoracic radiology fellow (DM, PGP), and discrepancies were resolved by consensus following concurrent review. The primary tumor was evaluated for size, lobar location, axial location within the lobe (inner, middle, or outer third), density (solid, pure ground glass opacity, or mixed density), cavitation, and air bronchograms. The metastatic lymph nodes were characterized as N0, N1, N2, or N3 per the American Joint Committee on Cancer (AJCC) 7th edition TNM staging manual \[[@B39-cancers-11-01360]\]. More distant lymph nodes were classified along with distant metastases. The presence of metastases in the lung, pleura, adrenal glands, bones, soft tissues/viscera, and brain were documented for each patient. The presence of axial and septal interstitial thickening that involved greater than half a lobe and extending far beyond the primary tumor was considered as lymphangitic spread of tumor.

The lung metastases, when present, were classified as diffuse or discrete. Diffuse lung metastasis was defined as randomly distributed innumerable small nodules (less than or equal to 6 mm) of uniform size that were distributed over a wide area in both lungs ([Figure 1](#cancers-11-01360-f001){ref-type="fig"}). Diffuse lung metastases were evaluated for axial and craniocaudal distribution. Patients with metastatic lung nodules that did not meet the above criteria for diffuse pattern were further subdivided based on their location relative to the dominant lung mass as within the same lobe, ipsilateral different lobe, and contralateral lung. As most of the subjects presented prior to the adoption of the AJCC 8th edition in the United States and our institution, the criteria laid out in the AJCC 7th edition staging manual were used to designate TNM stage and overall stage category \[[@B39-cancers-11-01360]\].

4.5. Statistical Analysis {#sec4dot5-cancers-11-01360}
-------------------------

Patient characteristics and imaging features were summarized using descriptive statistics. Continuous data were presented as medians with ranges, and categorical data were presented as frequencies with percentages. Comparisons were performed between *EGFR*-mutant and *EGFR* wild-type groups. Within the *EGFR*-mutant group, comparisons were also made between patients with diffuse lung metastases and those without diffuse lung metastases. Continuous characteristics between groups were compared using the Wilcoxon rank-sum test, and categorical features were compared using Fisher's exact test. All tests were two-tailed, and *p*-values less than 0.05 were considered significant.

In order to investigate the variables that can predict the presence of diffuse lung metastases among patients with *EGFR*-mutant patients, a multivariable logistic regression model was built. The criteria for choosing candidate predictors were *p*-value \< 0.20 based on univariate analysis and proper sample size.

5. Conclusions {#sec5-cancers-11-01360}
==============

In conclusion, *EGFR*-mutant NSCLC is associated with increased frequency of diffuse lung metastases. The presence of this diffuse pattern in *EGFR*-mutant NSCLC is associated with decreased propensity for the presence of other non-miliary pulmonary nodules. *EGFR* mutations in NSCLC have important treatment and prognostic implications and should be considered in the setting of suspected NSCLC with diffuse lung metastases. Although these distinct features cannot replace molecular testing in determining the presence of *EGFR* mutations, they may help identify patients who may benefit from expedited or repeat testing following unexpectedly negative genotyping.
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![Four patients with *EGFR*-mutated lung cancers and diffuse lung metastases. (**A**) 44-year-old female never-smoker presents with a central right hilar mass with mediastinal and right hilar lymphadenopathy and innumerable 2--3 mm pulmonary nodules bilaterally. Patient was subsequently diagnosed with non-small cell lung cancer (NSCLC) with *EGFR* exon 19 mutation. Note the air bronchograms in the primary tumor, a feature also described in *EGFR*-mutated NSCLC. (**B**) 66-year-old male never-smoker presents with a consolidative mass in the left upper lobe and lingula with miliary-like pattern of diffuse 2--3 mm pulmonary nodules bilaterally and mediastinal and left hilar lymphadenopathy. This patient was found to have NSCLC with *EGFR* exon 21 mutation. Again, note the air bronchogram in the primary tumor. (**C**) 74-year-old female never-smoker presenting with a dominant right upper lobe mass and diffuse innumerable 2--3 mm nodules bilaterally. Patient had an *EGFR* exon 19 mutation. (**D**) 61-year-old male never-smoker presents with diffuse 2--3 mm lung nodules with a dominant 2.3 cm left lower lobe spiculated nodule (not shown), which was positive for *EGFR* exon 19 mutation.](cancers-11-01360-g001){#cancers-11-01360-f001}

cancers-11-01360-t001_Table 1

###### 

Patients characteristics, tumor genotypes, and imaging features among all patients (*n* = 217).

  Characteristics             All (*n* = 217)   *EGFR*         *p*-Value \*     
  --------------------------- ----------------- -------------- ---------------- ---------
  Patients Characteristics                                                      
                                                               Median (range)   
  Age                         65 (26--90)       63 (26--90)    68 (42--84)      \<0.01
  Gender                                                       *n* (%)          
  Female                      123 (57%)         81 (69%)       42 (42%)         \<0.01
  Male                        94 (43%)          36 (31%)       58 (58%)         
  Race                                                                          
  Caucasian                   185 (85%)         94 (80%)       91 (91%)         0.03
  Asian                       19 (9%)           12 (10%)       7 (7%)           
  African-American            4 (2%)            3 (3%)         1 (1%)           
  Hispanic                    3 (1%)            3 (3%)         0 (0%)           
  Others/Unknown              6 (3%)            5 (4%)         1 (1%)           
  Smoking status                                                                
  Never                       88 (41%)          72 (62%)       16 (16%)         \<0.01
  Ever                        129 (59%)         45 (38%)       84 (84%)         
  Primary tumor features                                                        
  Size (mm)                   50 (10--134)      47 (11--134)   52 (10--115)     0.84
  Primary lesion lobar zone                                                     
  Both                        51 (24%)          29 (25%)       22 (22%)         0.18
  Central                     91 (42%)          54 (46%)       37 (37%)         
  Peripheral                  75 (35%)          34 (29%)       41 (41%)         
  Solid                                                                         
  No                          21 (10%)          13 (11%)       8 (8%)           0.5
  Yes                         196 (90%)         104 (89%)      92 (92%)         
  Air bronchograms                                                              
  No                          156 (72%)         84 (72%)       72 (72%)         \> 0.99
  Yes                         61 (28%)          33 (28%)       28 (28%)         
  Cavity                                                                        
  No                          198 (91%)         111 (95%)      87 (87%)         0.05
  Yes                         19 (9%)           6 (5%)         13 (13%)         
  Tumor Calcification                                                           
  No                          211 (97%)         112 (96%)      99 (99%)         0.22
  Yes                         6 (3%)            5 (4%)         1 (1%)           
  Nodal disease                                                                 
  Negative                    23 (11%)          19 (16%)       4 (4%)           \<0.01
  Positive                    194 (89%)         98 (84%)       96 (96%)         
  Metastatic sites                                                              
  Intrathoracic                                                                 
  Absent                      33 (15%)          21 (18%)       12 (12%)         0.26
  Present                     184 (85%)         96 (82%)       88 (88%)         
  Pleura                                                                        
  No                          100 (46%)         70 (60%)       30 (30%)         \<0.01
  Yes                         117 (54%)         47 (40%)       70 (70%)         
  Lung                                                                          
  No                          67 (31%)          34 (29%)       33 (33%)         0.56
  Yes                         150 (69%)         83 (71%)       67 (67%)         
  Diffuse lung                                                                  
  No                          193 (89%)         96 (82%)       97 (97%)         \<0.01
  Yes                         24 (11%)          21 (18%)       3 (3%)           
  Extrathoracic                                                                 
  Absent                      63 (29%)          33 (28%)       30 (30%)         0.88
  Present                     154 (71%)         84 (72%)       70 (70%)         
  Bone                                                                          
  No                          133 (61%)         68 (58%)       65 (65%)         0.33
  Yes                         84 (39%)          49 (42%)       35 (35%)         
  Brain                                                                         
  No                          140 (65%)         70 (60%)       70 (70%)         0.15
  Yes                         77 (35%)          47 (40%)       30 (30%)         
  Adrenal                                                                       
  No                          170 (78%)         101 (86%)      69 (69%)         \<0.01
  Yes                         47 (22%)          16 (14%)       31 (31%)         
  Soft tissue                                                                   
  No                          179 (82%)         92 (79%)       87 (87%)         0.11
  Yes                         38 (18%)          25 (21%)       13 (13%)         

\* *p*-Values provided are for comparison between *EGFR*-mutant and *EGFR*-wild type groups. Significant *p*-Values are highlighted.

cancers-11-01360-t002_Table 2

###### 

Patients characteristics and imaging features, among *EGFR*-mutant patients (*n* = 117).

  Characteristics                All (*n* = 117)   Diffuse Lung Metastases   *p*-Value \*     
  ------------------------------ ----------------- ------------------------- ---------------- --------
  Patients characteristics                                                                    
                                                                             Median (range)   
  Age                            63 (26--90)       58 (37--82)               64 (26--90)      0.16
  Size (mm)                      47 (11--134)      47 (17--99)               47 (11--134)     0.42
  Age                                              *n* (%)                   *n* (%)          
  \<63                           57 (49%)          14 (67%)                  43 (45%)         0.09
  ≥63                            60 (51%)          7 (33%)                   53 (55%)         
  Gender                                                                                      
  Female                         81 (69%)          11 (52%)                  70 (73%)         0.07
  Male                           36 (31%)          10 (48%)                  26 (27%)         
  Ethnicity                                                                                   
  Caucasian                      94 (80%)          15 (71%)                  79 (82%)         0.36
  Asian                          12 (10%)          3 (14%)                   9 (9%)           
  African American               3 (3%)            1 (5%)                    2 (2%)           
  Hispanic                       3 (3%)            0 (0%)                    3 (3%)           
  Others/Unknown                 5 (4%)            2 (10%)                   3 (3%)           
  Smoking status                                                                              
  Never                          72 (62%)          16 (76%)                  56 (58%)         0.15
  Ever                           45 (38%)          5 (24%)                   40 (42%)         
  *EGFR* subtype                                                                              
  Exon 19                        61 (52%)          12 (57%)                  49 (51%)         0.9
  Exon 21                        33 (28%)          5 (24%)                   28 (29%)         
  Exon 18                        13 (11%)          1 (5%)                    12 (13%)         
  Exon 20                        10 (9%)           3 (14%)                   7 (7%)           
  Primary tumor features                                                                      
  Size \>30 mm                                                                                
  No                             22 (19%)          3 (14%)                   19 (20%)         0.76
  Yes                            95 (81%)          18 (86%)                  77 (80%)         
  Location                                                                                    
  Both                           29 (25%)          9 (43%)                   20 (21%)         0.11
  Central                        54 (46%)          8 (38%)                   46 (48%)         
  Peripheral                     34 (29%)          4 (19%)                   30 (31%)         
  Solid                                                                                       
  No                             13 (11%)          3 (14%)                   10 (10%)         0.7
  Yes                            104 (89%)         18 (86%)                  86 (90%)         
  Air bronchograms                                                                            
  No                             84 (72%)          15 (71%)                  69 (72%)         \>0.99
  Yes                            33 (28%)          6 (29%)                   27 (28%)         
  Cavity                                                                                      
  No                             111 (95%)         19 (90%)                  92 (96%)         0.29
  Yes                            6 (5%)            2 (10%)                   4 (4%)           
  Calcification                                                                               
  No                             112 (96%)         21 (100%)                 91 (95%)         0.58
  Yes                            5 (4%)            0 (0%)                    5 (5%)           
  Nodal disease                                                                               
  Negative                       19 (16%)          1 (5%)                    18 (19%)         0.19
  Positive                       98 (84%)          20 (95%)                  78 (81%)         
  Metastases sites                                                                            
  Pleural                                                                                     
  No                             70 (60%)          11 (52%)                  59 (61%)         0.47
  Yes                            47 (40%)          10 (48%)                  37 (39%)         
  Extra-thoracic                                                                              
  Absent                         33 (28%)          6 (29%)                   27 (28%)         \>0.99
  Present                        84 (72%)          15 (71%)                  69 (72%)         
  Bone                                                                                        
  No                             68 (58%)          12 (57%)                  56 (58%)         \>0.99
  Yes                            49 (42%)          9 (43%)                   40 (42%)         
  Brain                                                                                       
  No                             70 (60%)          11 (52%)                  59 (61%)         0.47
  Yes                            47 (40%)          10 (48%)                  37 (39%)         
  Adrenal                                                                                     
  No                             101 (86%)         17 (81%)                  84 (88%)         0.48
  Yes                            16 (14%)          4 (19%)                   12 (12%)         
  Soft tissue                                                                                 
  No                             92 (79%)          17 (81%)                  75 (78%)         \>0.99
  Yes                            25 (21%)          4 (19%)                   21 (22%)         
  Other lung metastasis \>6 mm                                                                
  No                             49 (42%)          16 (76%)                  33 (34%)         \<0.01
  Yes                            68 (58%)          5 (24%)                   63 (66%)         

\* *p*-Values provided are for comparison between *EGFR*-mutant NSCLC patients with diffuse lung metastases versus those without diffuse lung metastases. Significant *p*-Values are highlighted.
